London CNN —
First, Novo Nordisk, the company behind Ozempic and Wegovy, outgrew its native Denmark. Now, it’s bigger than Tesla.
Shares in the pharmaceutical giant rose jumped more than 8% Thursday, pushing its market capitalization to $609 billion, about $40 billion more than Tesla’s valuation.
Investors rushed into Novo Nordisk’s stock after the company reported early-stage results from a trial of amycretin, an experimental weight loss drug that can be taken in pill form. Phase I trial data showed that participants lost 13.1% of their weight after 12 weeks.
Grégoire Biollaz, a senior
→ Continue reading at CNN - Business News
